EUVIMEDOpdag EUVIMED
Open access

Ki-67 Evaluation for Clinical Decision in Metastatic Lung Carcinoids: A Proof of Concept

Giuseppe Pelosi iD, Federica Massa, Gaia Gatti, Luisella Righi, Marco Volante, Nadia Birocco, Patrick Maisonneuve, Angelica Sonzogni, Sergio Harari, Adriana Albini, Mauro Papotti

Clinical Pathology · 2019-01 · 12

DOI: 10.1177/2632010x19829259 ↗

At a glance

Journal article in Clinical Pathology, published online on 2019-02-19. Written by Giuseppe Pelosi and 10 co-authors. Institution: Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy. Cited 32 times so far (Crossref); 19 references. The full text is freely available in PubMed Central. Funded by: associazione italiana per la ricerca sul cancro.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Accrual of metastatic pulmonary carcinoid patients for therapy is usually relied on clinical and histologic characterization, with no role for the proliferation activity as defined by Ki-67 labelling index (LI). A total of 14 carcinoid patients with tumour primaries (TP) and 19 corresponding tumour metastases (TM) were blindly reviewed by 2 different pathologists for necrosis, mitotic count, and Ki-67 LI. Ki-67 LI outperformed histologic subtyping, mitotic count, and necrosis with good to almost excellent (0.40-0.75) inter-observer agreement. About 10% cut-off Ki-67 LI predicted survival better than histology for TP and TM for both observers. The TM patients survived differently according to diverse treatments (somatostatin analogues [SSAs], analogues plus additional treatments except for platinum; platinum-based chemotherapy) in close correlation with 20% cut-off thresholds of Ki-67 LI, respectively. There was also a trend for an increase in Ki-67 LI in TM as compared with TP. This is the first proof of concept in which a clinical potential is preliminarily suggested for Ki-67 LI to better stratify pulmonary metastatic carcinoid patients for treatment according to a criterion of histology-independent biological aggressiveness.

Subjects

Author keywords

Ki-67 labelling indexcarcinoidhistologymetastasistherapy

Authors and institutions

  • Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy.
  • Inter-hospital Pathology Division, Science & Technology Park, IRCCS MultiMedica, Milan, Italy.
  • Department of Oncology, University of Turin and Pathology Unit, Molinette Hospital, City of Health and Science, Turin, Italy.
  • Department of Oncology, University of Turin and Pathology Unit, San Luigi Hospital, Turin, Italy.
  • Medical Oncology, Molinette Hospital, City of Health and Science, Turin, Italy.
  • Division of Epidemiology and Biostatistics, European Institute of Oncology (IEO), IRCCS, Milan, Italy.

ORCID profiles: Giuseppe Pelosi

Funding

  • associazione italiana per la ricerca sul cancro

Cite

APA

Pelosi, G., Massa, F., Gatti, G., Righi, L., Volante, M., Birocco, N., Maisonneuve, P., Sonzogni, A., Harari, S., Albini, A., & Papotti, M. (2019). Ki-67 Evaluation for Clinical Decision in Metastatic Lung Carcinoids: A Proof of Concept. Clinical Pathology, 12. https://doi.org/10.1177/2632010x19829259

Vancouver

Pelosi G, Massa F, Gatti G, Righi L, Volante M, Birocco N, et al. Ki-67 Evaluation for Clinical Decision in Metastatic Lung Carcinoids: A Proof of Concept. Clinical Pathology. 2019;12. doi:10.1177/2632010x19829259

BibTeX
@article{Pelosi2019,
  author = {Pelosi, Giuseppe and Massa, Federica and Gatti, Gaia and Righi, Luisella and Volante, Marco and Birocco, Nadia and Maisonneuve, Patrick and Sonzogni, Angelica and Harari, Sergio and Albini, Adriana and Papotti, Mauro},
  title = {Ki-67 Evaluation for Clinical Decision in Metastatic Lung Carcinoids: A Proof of Concept},
  journal = {Clinical Pathology},
  year = {2019},
  volume = {12},
  doi = {10.1177/2632010x19829259}
}
Start for free →